sunitinib viatris 50 mg hartkapseln
viatris pharma gmbh - sunitinibum - hartkapseln - sunitinibum 50 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium, povidonum, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - zytostatikum - synthetika
sunitinib zentiva 12.5 mg hartkapseln
helvepharm ag - sunitinibum - hartkapseln - sunitinibum 12.5 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium max. 0.20 mg, povidonum k 30, magnesii stearas, kapselhülle: e 172 (rubrum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - zytostatikum - synthetika
sunitinib zentiva 25 mg hartkapseln
helvepharm ag - sunitinibum - hartkapseln - sunitinibum 25 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium max. 0.41 mg, povidonum k 30, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - zytostatikum - synthetika
sunitinib zentiva 50 mg hartkapseln
helvepharm ag - sunitinibum - hartkapseln - sunitinibum 50 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium max. 0.81 mg, povidonum k 30, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - zytostatikum - synthetika
sunitinib krka 12,5 mg hartkapsel
krka, d.d. novo mesto - sunitinib malate - hartkapsel - 12,5 mg - sunitinib malate 16.71 mg - sunitinib
sunitinib krka 25 mg hartkapsel
krka, d.d. novo mesto - sunitinib malate - hartkapsel - 25 mg - sunitinib malate 33.41 mg - sunitinib
sunitinib krka 50 mg hartkapsel
krka, d.d. novo mesto - sunitinib malate - hartkapsel - 50 mg - sunitinib malate 66.83 mg - sunitinib
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastische mittel - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib eg 12,5 mg hartkapsel
eurogenerics afgekort "e.g." - sunitinib - hartkapsel - 12,5 mg - sunitinib 12.5 mg - sunitinib
sunitinib eg 25 mg hartkapsel
eurogenerics afgekort "e.g." - sunitinib - hartkapsel - 25 mg - sunitinib 25 mg - sunitinib